ERBB2 and pancreatic neoplasm: (d) We chose available PDX models to evaluate DTLL efficacy mainly due to the prominent difference in EGFR expression, but not HER‐2 expression; therefore, how the expression of HER2 might contribute to DTLL efficacy in pancreatic tumor needs to be further explored using more PDX models with different levels of HER2.46